



RESEARCH ARTICLE

REVISED **Comparison of clinical outcomes between active and permissive blood pressure management in extremely preterm infants [version 2; peer review: 2 approved]**Narendra Aladangady ^{1,2}, Ajay Sinha ^{2,3}, Jayanta Banerjee ^{4,5}, Felix Asamoah⁶, Asha Mathew¹, Phillipa Chisholm ¹, Steven Kempley ^{2,3}, Joan Morris ⁷¹Department of Neonatology, Homerton University Hospital, Homerton Healthcare NHS Foundation Trust, London, E9 6SR, UK²Centre for Paediatrics, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK³Department of Neonatology, The Royal London Hospital, Barts Health NHS Trust, London, UK⁴Department of Neonatology, Imperial College Healthcare NHS Trust, London, UK⁵Institute of Reproductive and Developmental Biology, Imperial College London, London, UK⁶Department of Statistics, NHS England and Improvement, London, UK⁷Environment, Prevention & Health Care, Population Health Research Institute, St George's University of London, London, UK**V2** **First published:** 24 Jan 2023, **3:7**
<https://doi.org/10.3310/nihropenres.13357.1>**Latest published:** 10 May 2023, **3:7**
<https://doi.org/10.3310/nihropenres.13357.2>**Abstract****Background**

There remains uncertainty about the definition of normal blood pressure (BP), and when to initiate treatment for hypotension for extremely preterm infants. To determine the short-term outcomes of extremely preterm infants managed by active compared with permissive BP support regimens during the first 72 hours of life.

Method

This is a retrospective medical records review of 23+0–28+6 weeks' gestational age (GA) infants admitted to neonatal units (NNU) with active BP support (aimed to maintain mean arterial BP (MABP) >30 mmHg irrespective of the GA) and permissive BP support (used medication only when babies developed signs of hypotension) regimens. Babies admitted after 12 hours of age, or whose BP data were not available were excluded.

Results

There were 764 infants admitted to the participating hospitals; 671

Open Peer Review**Approval Status**

	1	2
version 2		
(revision)		
10 May 2023		
version 1		
24 Jan 2023		

1. **Eugene M. Dempsey** , University College Cork, Cork, Ireland
Cork University Maternity Hospital, Cork, Ireland

2. **Liam Mahoney**, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK

Any reports and responses or comments on the article can be found at the end of the article.

(88%) were included in the analysis (263 **active BP support** and 408 **permissive BP support**). The mean gestational age, birth weight, admission temperature, clinical risk index for babies (CRIB) score and first haemoglobin of infants were comparable between the groups. Active BP support group infants had consistently higher MABP and systolic BP throughout the first 72 hours of life ($p < 0.01$). In the active group compared to the permissive group 56 (21.3%) vs 104 (25.5%) babies died, and 21 (8%) vs 51 (12.5%) developed >grade 2 intra ventricular haemorrhage (IVH). Death before discharge (adjusted OR 1.38 (0.88 – 2.16)) or IVH (1.38 (0.96 – 1.98)) was similar between the two groups. Necrotising enterocolitis (NEC) \geq stage 2 was significantly higher in permissive BP support group infants (1.65 (1.07 – 2.50)).

Conclusions

There was no difference in mortality or IVH between the two BP management approaches. Active BP support may reduce NEC. This should be investigated prospectively in large multicentre randomised studies.

Plain English summary

The problem: Doctors are still not clear what the normal blood pressure (BP) is for premature babies during the first three days of life. Furthermore, it is unclear when to start treatment for low BP in preterm babies born at or before 28 weeks of gestation.

What we did: We compared clinical outcomes of a group of preterm babies who were treated with medication to maintain BP above 30mmHg ('active BP treatment' group) to a group of babies who were treated when they developed signs of low BP ('permissive BP treatment' group) from two large Neonatal Intensive Care Units (NICU) in London, UK.

How we tested it: Preterm babies born between 23 and 28 weeks gestation were studied. Babies admitted after 12 hours of age, or whose BP information was not available were excluded. BP measurements for the first 72 hours of life, and clinical outcome details of babies from NICU admission to discharge home were collected from medical records.

What we found: There was no difference in the level of prematurity, birth weight, and severity of illness score at admission between the active BP treatment and permissive BP treatment group babies. Active BP treatment group babies had a higher BP throughout the first 72 hours of life. There was no important difference in the number of babies who died or developed moderate grade brain haemorrhage between the active BP treatment group compared to the permissive BP treatment group. A significantly lower number of the active BP treatment group babies developed necrotising enterocolitis (NEC, inflammation of gut).

Conclusions: There was no difference in death or brain haemorrhage in babies between the two BP treatment methods. Active BP treatment during the first 72 hours of life may reduce NEC in preterm babies. This should be studied in large multicentre clinical studies.

Keywords

Blood pressure, Preterm infants, Active BP support, Permissive BP support, Hypotension

Corresponding author: Narendra Aladangady (n.aladangady@nhs.net)

Author roles: **Aladangady N:** Conceptualization, Funding Acquisition, Investigation, Methodology, Project Administration, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing; **Sinha A:** Conceptualization, Funding Acquisition, Investigation, Methodology, Writing – Review & Editing; **Banerjee J:** Data Curation, Funding Acquisition, Investigation, Methodology, Writing – Review & Editing; **Asamoah F:** Data Curation, Formal Analysis, Writing – Review & Editing; **Mathew A:** Data Curation, Writing – Review & Editing; **Chisholm P:** Funding Acquisition, Methodology, Writing – Review & Editing; **Kempley S:** Conceptualization, Funding Acquisition, Investigation, Methodology, Writing – Review & Editing; **Morris J:** Formal Analysis, Funding Acquisition, Methodology, Project Administration, Supervision, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This project is funded by the National Institute for Health Research (NIHR) under its [Research for Patient Benefit (RfPB) Programme (Grant Reference Number PB-PG-0211-24147 assigned to Prof Aladangady. Co-applicants are Dr Sinha A, Dr Banerjee J, Dr Chisholm P, Prof Morris JK and Dr Kempley S)]. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © Crown copyright, 2023 Aladangady N *et al.*. This open access work is licensed under the [Open Government Licence v3.0](#)



How to cite this article: Aladangady N, Sinha A, Banerjee J *et al.* **Comparison of clinical outcomes between active and permissive blood pressure management in extremely preterm infants [version 2; peer review: 2 approved]** NIHR Open Research 2023, 3:7 <https://doi.org/10.3310/nihropenres.13357.2>

First published: 24 Jan 2023, 3:7 <https://doi.org/10.3310/nihropenres.13357.1>

REVISED Amendments from Version 1

The primary outcome (brain injury), data collected, and limitation sections were updated as per comments from reviewers.

Any further responses from the reviewers can be found at the end of the article

Plain English summary**The problem**

Doctors are still not clear what the normal blood pressure (BP) is for premature babies during the first three days of life. Furthermore, it is unclear when to start treatment for low BP in preterm babies born at or before 28 weeks of gestation.

What we did

We compared clinical outcomes of a group of preterm babies who were treated with medication to maintain BP above 30mmHg ('active BP treatment' group) to a group of babies who were treated when they developed signs of low BP ('permissive BP treatment' group) from two large Neonatal Intensive Care Units (NICU) in London, UK.

How we tested it

Preterm babies born between 23 and 28 weeks gestation were studied. Babies admitted after 12 hours of age, or whose BP information was not available were excluded. BP measurements for the first 72 hours of life, and clinical outcome details of babies from NICU admission to discharge home were collected from medical records.

What we found

There was no difference in the level of prematurity, birth weight, and severity of illness score at admission between the active BP treatment and permissive BP treatment group babies. Active BP treatment group babies had a higher BP throughout the first 72 hours of life. There was no important difference in the number of babies who died or developed moderate grade brain haemorrhage between the active BP treatment group compared to the permissive BP treatment group. A significantly lower number of the active BP treatment group babies developed necrotising enterocolitis (NEC, inflammation of gut).

Conclusions

There was no difference in death or brain haemorrhage in babies between the two BP treatment methods. Active BP treatment during the first 72 hours of life may reduce NEC in preterm babies. This should be studied in large multicentre clinical studies.

Background

There is considerable uncertainty in the definition of hypotension and when to treat hypotension in very preterm infants^{1,2}. There is ambiguity regarding treating hypotension based on a specific blood pressure (BP) value and the subsequent clinical outcomes of preterm infants³⁻⁷. Clinicians tend to treat low BP in premature infants with an aim to improve or stabilise cerebral

perfusion. However, evidence for the effect of mean arterial BP (MABP) on cerebral perfusion is conflicting^{4,8-12}. In some studies there was an association between babies with a mean MABP ≤ 30 mm Hg having higher rates of intraventricular haemorrhage (IVH)^{7,13}. Recently Buttici and colleagues have reported that a significantly higher numbers of very preterm infants with MABP ≤ 30 mm Hg had abnormal brain MRI findings compared to babies with MABP > 30 mm Hg during the first 48 hours of life⁸. However there is limited evidence to suggest that anti-hypotensive therapies improve outcomes for preterm infants, and growing concern that these therapies may be harmful^{14,15}. Due to a lack of clear evidence, the clinical practice of treating hypotension for preterm infants varies among clinicians across the world¹⁶⁻¹⁹.

A number of trials have examined the drugs used to support BP^{6,20,21}, but the studies comparing outcomes of extreme preterm infants treated at different BP intervention levels are limited²². The aim of this study was to compare the short-term outcomes of extremely preterm babies managed in two hospitals which had different policies for the management of BP, one with an active (MABP maintained > 30 mm Hg) and one with a permissive (only treated if baby develops symptomatic hypotension) BP support regimen during the first 72 hours of life.

Methods**Study design**

This was a retrospective medical records review study. The neonatal unit outcomes of all extreme preterm babies were compared between Hospital A, which aims to maintain BP above 30 mmHg irrespective of the gestational age (GA) (**active BP support group**) and Hospital B, which uses medication only if babies developed clinical signs of low BP (**permissive BP support group**). The criteria used for intervention in the permissive BP support group was mean arterial blood pressure (MABP) lower than the gestational age in weeks of the infant with clinical evidence of poor perfusion (poor skin colour/capillary refill time > 3 secs, urine output < 1 ml/kg/hour from weighing of urine, lactate > 3 mmol/l, worsening base deficit/base deficit > 8 mmol/l and/or increasing oxygen requirement). Both centres had a comparable BP management protocol, consisting of initial 0.9% saline bolus of 10 to 20 ml/kg, followed by dopamine, and then the addition of other inotropes if required, to achieve the predetermined active and permissive BP support.

Participants

All preterm infants born at 23⁺⁰-28⁺⁶ weeks gestation admitted to two neonatal units over 4 years from 1st January 2007 to 31st December 2010 were eligible. Babies admitted after 12 hours of age, with major congenital abnormalities, and whose intensive care observational charts (to collect BP data) were not traceable, were excluded.

Primary and secondary outcome measures

The primary outcomes were death or parenchymal brain abnormality (all grades of IVH) on cranial ultrasound scan

before discharge home. Secondary outcome measures were BP during the first three days after birth and \geq stage 2 necrotising enterocolitis (NEC).

Data collected

Pregnancy complications (presence of any one pregnancy complications such as Premature Prolonged Rupture of Membrane (PPROM), Abruption, Polyhydramnios, Oligohydramnios, Maternal medical condition (e.g., Chronic Renal Failure, Sickle Cell Crisis, Diabetes), High Body Mass Index, antenatal Doppler findings, chorioamnionitis or hypertension), condition of the baby at birth (clinical risk index for babies (CRIB) score, cord pH and lactate), and demographics of infants were collected using electronic patient record (EPR) and BadgerNet (UK national neonatal EPR). Hourly systolic (SBP) and mean arterial (MABP) BP data were collected from intensive care charts. Inotropic medications, fluid bolus, red blood cell and other blood products used were gathered from medication and/or prescription charts. Short-term outcomes such as necrotising enterocolitis (NEC), intraventricular haemorrhage (IVH)/brain injury identified by brain ultrasound scan (USS), bronchopulmonary dysplasia (BPD), patent ductus arteriosus (PDA), death or discharge, and duration of BAPM levels of care provided were collected from BadgerNet. NEC was defined by Bell's stage of classification²³. BPD was defined as oxygen dependency at 36 weeks post conceptional age²⁴. PDA was confirmed by echocardiography. Accuracy of BP data was confirmed by two researchers randomly verifying 10% of BP data collected.

Statistical analysis

The outcomes for the babies treated by active and permissive BP management approaches were compared. Adjustments were

made for all available confounders between the two groups. The association of the babies' BP with outcomes was examined, in order to provide evidence that it is the difference in blood pressure management between the two groups rather than other unspecified treatments that were affecting the outcomes. For continuous variables student t-tests and for categorical variables chi-squared tests or Fisher-exact tests were performed. The 95% confidence interval (CI) of the means was calculated. Univariate and multivariate regression analysis to adjust for birth weight, GA, sex, chorioamnionitis and ethnicity were performed. All statistical inference was based on the two-sided test with a significance level of $p < 0.05$. Data was analysed using *Stata* v12 software, an open-access alternative that can perform an equivalent function is RStudio

Ethics approval

The study was approved by NRES Committee London–Westminster in 2011 and formal consent was not required as we used anonymised routinely collected clinical data (REC Ref No – 11/LO/1117).

Results

A total of 764 infants born between 23⁺⁰ to 28⁺⁶ weeks' gestation were admitted to participating hospitals; 279 infants in the **active BP support group** and 485 infants in the **permissive BP support group** were studied²⁵. 93 (11%) infants were excluded resulting in 263 infants in the **active BP support group** and 408 infants in the **permissive BP support group** being included in the study (Figure 1). The mean gestational age, birth weight, admission temperature, CRIB score and first haemoglobin (Hb) of infants were comparable between the two groups. Babies from the permissive BP support group were more acidotic at birth. Maternal ethnicity was significantly different




Figure 1. Diagram of patients included to the study.

between the two centres (Table 1). A significantly higher number of babies in the permissive group were born to mothers with pregnancy complications. There was no difference in antenatal steroid administration between the groups. A significantly higher number of babies in the active group were out-born (Table 1).

BP measurements and management

A significantly higher number of active BP support group infants were started on and treated for a longer duration with

inotropic medications (Table 2). Infants from the permissive group received a significantly larger volume of blood transfusions. There was no significant difference in other blood products or crystalloid received between the two groups (Table 3). In both groups, MABP and SBP increased over time, with a slight decrease in SBP from the 6th to 18th hour and then a consistent increase till 72 hours of life. Infants managed by active BP support had consistently higher MABP and SBP throughout the first 72 hours of life compared to permissive group of infants ($p < 0.01$; Figure 2).

Table 1. Maternal and infant characteristics.

Variable	Categories/ measures	Active BP support group (n - 263)	Permissive BP support group (n - 408)	P-value
Pregnancy complications	Yes (%)	201 (88.9)	342 (93.7)	0.04
Antenatal Doppler abnormality	Abnormal (%)	34 (17.4)	66 (19.1)	0.61
Chorioamnionitis	Yes (%)	31 (11.8)	58 (14.2)	0.37
Pregnancy Induced Hypertension (PIH)	Yes (%)	31 (11.8)	54 (13.2)	0.58
Antepartum haemorrhage (APH)	Yes (%)	44 (16.7)	92 (22.6)	0.06
Antenatal steroid	Yes (%)	247 (93.9)	381 (93.6)	0.87
Infant Sex	Male (%)	149 (56.7)	205 (50.3)	0.11
	Female (%)	114 (43.4)	203 (49.8)	
Gestational Age (weeks)	Mean (95% CI)	26.2 (25.9 – 26.4)	26.2 (26.0 – 26.3)	0.94
Birthweight (g)	Mean (95% CI)	853.1 (824.9 – 881.2)	834.2 (814.3 – 854.2)	0.27
Ethnicity n (%)	Caucasians (%)	85 (32.3)	173 (42.5)	0.001
	Black African & Black Caribbean (%)	72 (27.4)	148 (36.4)	
	Asian (%)	94 (35.7)	73 (17.9)	
	Mixed (%)	12 (4.6)	13 (3.2)	
Place of birth n (%)	Inborn (%)	187 (71.1)	322 (78.9)	0.02
	Out-born (%)	76 (28.9)	86 (21.1)	
Admission Temperature (°C)	Mean (95% CI)	36.4 (36.3 – 36.5)	36.4 (36.3 – 36.5)	0.98
Base excess (mmol/l)	Mean (95% CI)	-5.5 (-6.1 to -4.9)	-6.4 (-6.9 to -5.9)	0.03
First Hb (g/dl)	Mean (95% CI)	14.7 (14.4 – 15.1)	14.7 (14.4 – 14.9)	0.69
CRIB Score	Mean (95% CI)	11.3 (10.9 – 11.7)	10.9 (10.6 – 11.2)	0.16

Hb – Haemoglobin

CRIB Score - Clinical Risk Index for Babies scoring system

Table 2. Management of blood pressure (BP).

Inotrope	Categories/ measures	Active BP support group (n= 263)	Permissive BP support group (n=408)	P-value
Inotrope n (%)	Yes < 72 hrs	145 (55.1)	137 (33.6)	0.001
	Yes ≥72 hrs	18 (6.8)	25 (6.1)	
Day of starting inotrope if late	median (range)	17 (4 – 96)	21 (4 – 92)	0.88
Total Inotrope days (Early start)*	median (range)	4 (1 – 41)	2 (1 – 16)	<0.01
Total Inotrope days (Late start)**	median (range)	7 (4 – 41)	2 (4 – 14)	0.01
Inotrope drugs n (%)	Dopamine	112 (42.6)	111 (27.2)	0.0001
Inotrope drugs n (%)	Any Combination•	50 (19.0)	49 (12.0)	0.01

*Early start: inotropes started <72 hours, **Late start: >72 hours

•Any Combination includes: Dopamine + Dobutamine + Noradrenaline +Adrenaline

Table 3. Blood products and crystalloids used during the first 72 hours of life.

Colloids/Crystalloids	Active BP support group (n= 263); Mean (95% CI)	Permissive BP support group (n=408); Mean (95% CI)	P-value
RBC (ml/kg)	25.4 (23.5 – 27.4)	29.5 (27.5 – 31.5)	0.006
FFP (ml/kg)	19.70 (17.64 – 21.75)	22.01 (19.64 – 24.39)	0.17
Cryoprecipitate (ml/kg)	15.63 (13.47 – 17.77)	17.19 (15.5 – 18.89)	0.29
Platelets	15.74 (14.55 – 16.93)	17.61 (14.4 – 20.79)	0.23
Normal saline bolus (ml/kg)	15.05 (13.54 – 16.55)	14.32 (13.84 – 16.81)	0.60
Total volume (excluding RBC)	11.5 (9.6 – 13.5) (n=168; (63.9%))	15.4 (13.1 – 17.7) (n=150; (36.8%))	0.014
Total volume (including RBC)	29.2 (25.8 – 32.6) (n=191; (72.6%))	31.9 (28.1 – 35.7) (n=270; (66.2%))	0.32

RBC – Red blood cells; FFP – Fresh Frozen Plasma; n – number of infants (%)

BP support and clinical outcomes

Death before discharge was similar between the two groups. 56 (21.3%) babies died in the active group compared to 104 (25.5%) in the permissive group (p 0.21). The odds ratio (aOR) of death in the permissive compared with the active regimen remained non-significant even after adjustment for risk factors: 1.38 (0.88 – 2.16). 75 (28.5%) babies developed all grades of IVH in the active group compared to 140 (34.3%) in the permissive group (p 0.12). 21 (8.0%) infants developed >grade 2 IVH in the active group compared to 51 (12.5%) in the permissive group but this was not significant (p 0.07). The aOR of all grades of IVH and >stage 2 IVH in the permissive compared with active regimen were 1.38 (0.96 – 1.98) and 1.71 (0.99 – 2.97)

respectively. A significantly lower number of infants in the active BP support group [n=37 (14.1%)] developed ≥stage 2 NEC compared to the permissive group [85 (20.8%), p 0.03]. The aOR of ≥stage 2 NEC in the active compared with permissive regimen was 1.65 (1.07 – 2.50). A significantly higher number of the active BP support group infants [n=63 (25.7%)] received medical treatment for haemodynamically significant PDA compared to the permissive group [64 (16.9%), p 0.01]. There was no difference in PDA requiring surgical treatment between the active [18 (9.0%)] and the permissive groups [29 (8.4%), p 0.82]. There was slightly increased incidence of BPD in infants in the active BP regimen [107 (41.8%) vs. 138 (34.8%), p 0.07] (Table 4).




Figure 2. Comparison of 6 hourly mean arterial blood pressure (MABP) (Figure 2a), systolic blood pressure (SBP) (Figure 2b) and separated invasive and non-invasive MABP (Figure 2c) and SBP (Figure 2d).

The median (IQR) special care baby unit (SCBU) care days was significantly lower for infants in the active group [34 (123-42)] compared to the permissive BP regimen [40 (30-51); $p < 0.01$]. Permissive BP support group infants received significantly lower duration of High Dependency (HD) care days [aOR 0.82 (0.71 - 0.95)] and longer duration of SCBU care days [aOR 1.20 (1.08 - 1.36)] compared to the active group (Table 4).

Discussion

The present study investigated the short-term clinical outcomes of a large number of infants born between 23⁺⁰ to 28⁺⁶ weeks gestation managed in two different hospitals using active or permissive BP support. The rate of death or brain injury on cranial ultrasound scan before discharge from the neonatal unit did not differ significantly between the two groups. Active BP support group infants had significantly lower \geq stage 2 NEC. Clinically relevant PDA was significantly lower in infants managed by permissive BP support. Infants treated by active BP support received significantly longer HD care days and the permissive BP support group infants received significantly longer SCBU care days.

Similar to our study findings, there was no difference noticed in death and brain injury on cranial USS at 36 weeks post conceptional age (PCA) in infants born before 28 weeks gestation in a recently published double blind randomised clinical trial (RCT) (n=58 infants) of infants randomised to standard BP management (dopamine) or restrictive BP management (5% dextrose placebo) when MABP dropped below the infant's gestational age²². The permissive approach has been actively promoted in recent years¹ but there is some evidence which supports the use of the active approach. Cerebral blood flow may be auto-regulated at MABP of ≥ 30 mmHg and be pressure passive < 30 mmHg in preterm infants¹². Miall-Allen *et al.* have reported that infants born at mean GA of 27 weeks who had MABP of < 30 mm Hg developed significantly more severe IVH and early death than those with a MABP of > 30 mm Hg^{7,26}. Similar to the present study findings, Pereira *et al.* in a RCT of active (maintain MABP > 30 mm Hg), moderate (MABP equivalent to GA) and permissive (symptomatic hypotension) management of BP found no difference in all grades of IVH or death between the groups, but there was a higher rate of grade 2-4 IVH in the moderate arm group in comparison to active group⁶. Higher number of babies in the permissive group

Table 4. BP management and short-term outcomes.

Outcomes	Active BP support group (n = 263); n (%)	Permissive BP support group (n = 408); n (%)	Unadjusted odds of (OR) Permissive Vs Active BP Support group (95% CI)	Adjusted odds of (aOR) Permissive Vs Active BP Support group (95% CI)
Death before discharge	56 (21.3)	104 (25.5)	1.27 (0.87 – 1.83)	1.38 (0.88 – 2.16)
Periventricular leukomalacia (PVL)	1 (0.4)	2 (0.5)	-	-
All grades of IVH	75 (28.5)	140 (34.3)	1.31 (0.94 – 1.83)	1.38 (0.96 – 1.98)
IVH: >grade 2	21 (8.0)	51 (12.5)	1.65 (0.97 – 2.80)	1.71 (0.99 – 2.97)
NEC: All grades	74 (28.1)	119 (29.2)	1.05 (0.75 – 1.48)	1.06 (0.75 – 1.50)
NEC: ≥Stage 2	37 (14.1)	85 (20.8)	1.61 (1.05 – 2.45)	1.65 (1.07 – 2.50)
PDA: Medical treatment	63 (25.7)	64 (16.9)	0.66 (0.47 – 0.94)	0.61 (0.41 – 0.89)
PDA: Med + Surgical treatment	18 (9.0)	29 (8.4)		
BPD	107 (41.8)	138 (34.8)	0.75 (0.54 - 1.03)	0.74 (0.53 – 1.02)
Length of stay (days); median (IQR)			Difference in mean days (unadjusted) Permissive vs Active BP support	Difference in mean days (adjusted) Permissive vs Active BP support*
Intensive Care days	24 (11 – 44)	23 (9 – 43)	0.94 (0.79 – 1.11)	0.90 (0.77 – 1.05)
High Dependency days	29 (13 – 42)	25 (15 – 36)	0.82 (0.70 - 0.95)	0.82 (0.71 - 0.95)
Special Care Baby Unit days	34 (123- 42)	40 (30 – 51)	1.21 (1.08 - 1.36)	1.20 (1.08 - 1.36)

OR – Odds Ratio

aOR - adjusted for birth weight, gestational age, sex, antenatal steroids and chorioamnionitis

Significant PDA – means Patent Ductus Arteriosus (PDA) that was treated medically by the attending clinicians

BPD – Bronchopulmonary Dysplasia (Oxygen dependency at 36 weeks post conceptual age)

developed >grade 2 IVH in the present study but it was not statistically significant; the mortality and IVH is comparable to the national average²⁷.

NEC ≥stage 2 was significantly lower in infants managed by active BP support in the present study. There is no comparable published study in the literature, and we speculate this could be because of improved intestinal perfusion during the first 72 hours of life. However, Batton *et al.* investigated preterm babies (23–26 weeks) who did or did not receive anti-hypotensive therapy and found no association between BP and development of severe NEC. There was no association between infants who developed one episode of isolated hypotension during the first 72 hours of life and NEC, irrespective of whether they were treated for hypotension or not, in a subgroup of EPIPAGE 2 cohort study²⁸. In a retrospective case control study, Haefeli *et al.* reported that hypotension did not increase the risk of NEC in infants with PDA²⁹. Similar to the present study, Faust and colleagues reported that severe NEC was lower among babies with high BP compared to babies with low BP during the first 24 hours of life³. Maternal pregnancy complications were higher among the permissive group. Maternal pregnancy induced hypertension has been reported to increase the risk for developing neonatal NEC. Researchers speculate uteroplacental insufficiency could lead to fetal hypoxia, which

may induce a hypoxic-ischemic state in the intestine or in its mucosa in the antenatal period³⁰. In animal experiments, hypoxia and ischaemia of the gut wall are important in the pathogenesis of gut injury and NEC^{31,32}. We have shown that, following a blood transfusion for preterm babies (<28 weeks gestation) in need of the transfusion, both BP (SBP and MABP) and intestinal perfusion increases proportionately during the first week of life³³, and that the increase in intestinal perfusion is more pronounced than cerebral perfusion³⁴.

There was no difference in gestational age, birth weight, sex and severity of illness at birth between the two groups of infants studied. Hb at birth has been reported to be associated with mortality and short-term outcomes in very preterm infants³⁵, but there was no difference in Hb at birth between the active and permissive groups. Antenatal steroid administration is similar between the groups and it is comparable to the national average³⁶. A significantly higher number of babies were out-born in the active group and a significantly higher number of babies were born to mothers with complications of pregnancy in the permissive group; both factors are known to affect the outcomes of very preterm infants^{37,38}. As expected, a significantly higher number of babies received inotropic medications, and for a longer duration in active group. The overall percentage of inotrope use was higher in both groups (61.9% in active

group and 39.7% in permissive group). Babies in the permissive group received a higher volume of red blood cell (RBC) transfusions, which has been reported to be associated with adverse outcomes³⁹. Fluid bolus during the first 48 hours of life may be associated with IVH in preterm infants⁴⁰. However, there was no difference in the total volume of 0.9% saline bolus or combined total normal saline and blood products received by two groups in our study. In both groups BP steadily increased over the first 72 hours of life as noticed by other researchers^{41,42}. However, the systolic BP and MABP were significantly higher throughout the first 72 hours of life in the active support group compared to the permissive group of infants. Hence, the study findings are likely due to the difference in BP management regimens.

There was a significant difference in ethnicity among infants studied; Asian ethnicity was higher in the active unit, with Black and White ethnicities higher in the permissive group. It is well documented that babies from Black ethnic groups are at increased risk for NEC⁴³, and the incidence of NEC was also noted to be higher among babies from the Asian ethnic group compared to white babies^{37,44,45}. Babies managed at the hospital with active BP support had a significantly longer duration of high dependency care days, as most of these babies were out-born and therefore transferred back to their local hospital once stable enough to be transferred, spending their SC days at the local hospital. In contrast, most babies in permissive BP support group were in-born and within the hospital catchment area, and remained in the same hospital until discharged home, resulting in significantly longer special care days. BPD was lower among babies treated with permissive BP support compared to active support group; this could be due to higher use of inotropic medication or overall ventilator support strategy in the active BP support group. Faust K *et al.*, in their observational cohort study found higher rates of BPD amongst babies with lower MABP³. Higher number of babies in the active BP support group received treatment for PDA; this is likely due to variation in clinical practice of treating PDA between centres⁴⁶.

Strengths and limitations

We have investigated a large number of infants with active and permissive BP support approach from two tertiary neonatal units; one unit followed the active and the second unit the permissive approach. Previous studies investigating BP management, use of inotropes and clinical outcomes of preterm infants have included less than 100 infants born at ≤ 30 weeks gestational age^{5-7,22}. We have excluded ex-utero babies who were admitted to participating units after 12 hours of age to avoid bias due to difference in BP management practice in referring hospitals. Confounding factors which may influence the clinical outcomes studied were taken into consideration to avoid bias and make the study findings more reliable^{47,48}. Both babies with invasive and non-invasive BP monitored were included to reflect the actual clinical practice. There was a significant difference in both SBP and MABP throughout the first 72 hours of life between the active and permissive BP support group of infants studied. The main limitation of the study is that we have compared outcomes of infants between two hospitals based on BP management practice but not investigated other practice differences which could impact on outcomes of

extremely preterm infants. The other limitation is the retrospective nature of the study, but only eight infants were excluded because of missing BP data. Also, except for the actual hourly BP data, the rest of the data were collected from prospectively entered EPR. The data on actual time of starting, duration of time BP below threshold and dosage of inotropes used was not collected. We have not collected data on sedation and paralysis which could affect BP^{49,50}. Time of umbilical cord clamping was not collected and placental transfusion is known to influence initial BP and outcomes of preterm infants⁵¹. We have not collected details of pregnancy complications except antenatal Doppler, Chorioamnionitis, Pregnancy Induced Hypertension and Antepartum hemorrhage. Delivery room strategies such as resuscitation/ventilation and thermoregulation were not evaluated but the admission temperature and CRIB Score were similar between the active and permissive BP support groups. Ventilation strategies in the neonatal unit, and feeding strategies in particular breast milk, age at commencement and donor breast milk details were not analysed. Probiotic was not used in both groups.

Conclusion

This is one of the largest studies comparing clinical outcomes of babies managed by active and permissive BP support in preterm infants. The different policies were associated with differences in achieved BP and circulatory support treatments. There was no difference in mortality or IVH between the two BP management approaches. However, babies in the active BP support group had less severe IVH. There was some suggestion that babies in the active BP support group had a lower risk of NEC. This cohort study suggests some potentially important clinical differences which should be investigated prospectively in large multicentre randomised controlled studies, and the results of this study can be used to inform sample size calculations for such studies.

Data availability

Underlying data

Figshare: Data supporting "Comparison of clinical outcomes between Active and Permissive blood pressure management in extremely preterm infants". <https://doi.org/10.24376/rd.sgul.21362469>²⁵.

This project contains the following underlying data:

- Documentation_16102022.xlsx (Excel file describing the data with all variables labelled (including definition of abbreviations), units of measurement and formats provided.)
- Treatment_BP_Comparison_16102022.csv (Data file in CSV format. Hospital 1 represents 'Permissive blood pressure management group' and Hospital 2 represents 'Active blood pressure management group' of infants.)
- readme.txt (Description of 16102022.xlsx and 16102022.csv files and basic description of study method and data collected)

Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).

References

- Barrington K, El-Khuffash A, Dempsey E: **Intervention and Outcome for Neonatal Hypotension.** *Clin Perinatol.* 2020; **47**(3): 563–574.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Cantinotti M, Giordano R, Scalise M, et al.: **Strengths and limitations of current pediatric blood pressure nomograms: a global overview with a special emphasis on regional differences in neonates and infants.** *Hypertens Res.* 2015; **38**(9): 577–587.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Faust K, Härtel C, Preuß M, et al.: **Short-term outcome of very-low-birthweight infants with arterial hypotension in the first 24 h of life.** *Arch Dis Child Fetal Neonatal Ed.* 2015; **100**(5): F388–F392.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Lightburn MH, Gauss CH, Williams DK, et al.: **Observational study of cerebral hemodynamics during dopamine treatment in hypotensive ELBW infants on the first day of life.** *J Perinatol.* 2013; **33**(9): 698–702.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Dempsey EM, Al Hazzani F, Barrington KJ: **Permissive hypotension in the extremely low birthweight infant with signs of good perfusion.** *Arch Dis Child Fetal Neonatal Ed.* 2009; **94**(4): F241–F244.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Pereira SS, Sinha AK, Morris JK, et al.: **Blood pressure intervention levels in preterm infants: pilot randomised trial.** *Arch Dis Child Fetal Neonatal Ed.* 2019; **104**(3): F298–F305.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Miall-Allen VM, de Vries LS, Whitelaw AG: **Mean arterial blood pressure and neonatal cerebral lesions.** *Arch Dis Child.* 1987; **62**(10): 1068–1069.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Butticci R, Habre C, Hernandez A, et al.: **Early arterial pressure monitoring and term-equivalent age MRI findings in very preterm infants.** *Pediatr Res.* 2022; **92**(3): 822–828.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Alderliesten T, Lemmers PMA, van Haastert IC, et al.: **Hypotension in Preterm Neonates: Low Blood Pressure Alone Does Not Affect Neurodevelopmental Outcome.** *J Pediatr.* 2014; **164**(5): 986–991.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Tyszczuk L, Meek J, Elwell C, et al.: **Cerebral Blood Flow Is Independent of Mean Arterial Blood Pressure in Preterm Infants Undergoing Intensive Care.** *Pediatrics.* 1998; **102**(2 Pt 1): 337–341.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Tsuji M, Saul JP, du Plessis A, et al.: **Cerebral Intravascular Oxygenation Correlates With Mean Arterial Pressure in Critically Ill Premature Infants.** *Pediatrics.* 2000; **106**(4): 625–632.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Munro MJ, Walker AM, Barfield CP: **Hypotensive Extremely Low Birth Weight Infants Have Reduced Cerebral Blood Flow.** *Pediatrics.* 2004; **114**(6): 1591–1596.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Bada HS, Korones SB, Perry EH, et al.: **Mean arterial blood pressure changes in premature infants and those at risk for intraventricular hemorrhage.** *J Pediatr.* 1990; **117**(4): 607–614.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Batton B, Li L, Newman NS, et al.: **Use of Antihypertensive Therapies in Extremely Preterm Infants.** *Pediatrics.* 2013; **131**(6): e1865–e1873.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Batton B, Li L, Newman NS, et al.: **Early blood pressure, antihypertensive therapy and outcomes at 18–22 months' corrected age in extremely preterm infants.** *Arch Dis Child Fetal Neonatal Ed.* 2016; **101**(3): F201–F206.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Stranak Z, Semberova J, Barrington K, et al.: **International survey on diagnosis and management of hypotension in extremely preterm babies.** *Eur J Pediatr.* 2014; **173**(6): 793–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Bhojani S, Banerjee J, Rahman M: **Management of neonatal hypotension – a national questionnaire survey.** *Infant.* 2010; **6**(5): 152–154.
[Reference Source](#)
- Dempsey EM, Barrington KJ: **Diagnostic criteria and therapeutic interventions for the hypotensive very low birth weight infant.** *J Perinatol.* 2006; **26**(11): 677–681.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Sehgal A, Osborn D, McNamara PJ: **Cardiovascular support in preterm infants: A survey of practices in Australia and New Zealand.** *J Paediatr Child Health.* 2012; **48**(4): 317–323.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Sassano-Higgins S, Friedlich P, Seri I: **A meta-analysis of dopamine use in hypotensive preterm infants: blood pressure and cerebral hemodynamics.** *J Perinatol.* 2011; **31**(10): 647–655.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Valverde E, Pellicer A, Madero R, et al.: **Dopamine Versus Epinephrine for Cardiovascular Support in Low Birth Weight Infants: Analysis of Systemic Effects and Neonatal Clinical Outcomes.** *Pediatrics.* 2006; **117**(6): e1213–e1222.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Dempsey EM, Barrington KJ, Marlow N, et al.: **Hypotension in Preterm Infants (HIP) randomised trial.** *Arch Dis Child Fetal Neonatal Ed.* 2021; **106**(4): 398–403.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Bell MJ, Ternberg JL, Feigin RD, et al.: **Neonatal Necrotizing Enterocolitis. Therapeutic Decisions Based upon Clinical Staging.** *Ann Surg.* 1978; **187**(1): 1–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Jobe AH, Bancalari E: **Bronchopulmonary Dysplasia.** *Am J Respir Crit Care Med.* 2001; **163**(7): 1723–1729.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Aladangady N, Morris J, Sinha A, et al.: **Data supporting “Comparison of clinical outcomes between Active and Permissive blood pressure management in extremely preterm infants”.** St George's, University of London - 2022.
<http://www.doi.org/10.24376/rd.sgul.21362469.v1>
- da Costa CS, Czosnyka M, Smielewski P, et al.: **Optimal Mean Arterial Blood Pressure in Extremely Preterm Infants within the First 24 Hours of Life.** *J Pediatr.* 2018; **203**: 242–248.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Costeloe KL, Hennessy EM, Haider S, et al.: **Short term outcomes after extreme preterm birth in England: Comparison of two birth cohorts in 1995 and 2006 (the EPICure studies).** *BMJ.* 2012; **345**: e7976.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Durrmeyer X, Marchand-Martin L, Porcher R, et al.: **Abstention or intervention for isolated hypotension in the first 3 days of life in extremely preterm infants: association with short-term outcomes in the EPIPAGE 2 cohort study.** *Arch Dis Child Fetal Neonatal Ed.* 2017; **102**(6): 490–496.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Haefeli S, Kordasz M, Tsai C, et al.: **Risk Factors for Necrotizing Enterocolitis in Infants With Patent Arterial Duct. A Retrospective Matched Paired Analysis.** *Front Pediatr.* 2020; **8**: 179.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Yang CC, Tang PL, Liu PY, et al.: **Maternal pregnancy-induced hypertension increases subsequent neonatal necrotizing enterocolitis risk: A nationwide population-based retrospective cohort study in Taiwan.** *Medicine (Baltimore).* 2018; **97**(31): e11739.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Cassuto J, Cedgård S, Haglund U, et al.: **Intramural blood flows and flow distribution in the feline small intestine during arterial hypotension.** *Acta Physiol Scand.* 1979; **106**(3): 335–342.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Redfors S, Hallbäck DA, Haglund U, et al.: **Blood flow distribution, villous tissue osmolality and fluid and electrolyte transport in the cat small intestine during regional hypotension.** *Acta Physiol Scand.* 1984; **121**(3): 193–209.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Banerjee J, Leung TS, Aladangady N: **Blood transfusion in preterm infants improves intestinal tissue oxygenation without alteration in blood flow.** *Vox Sang.* 2016; **111**(4): 399–408.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Murphy C, Banerjee J, Leung T, et al.: **Blood Transfusion Causes More Profound Changes In Splanchnic Oxygenation Compared With Brain.** In: *Neonatal Society. Reference Source*
- Banerjee J, Asamoah FK, Singhi D, et al.: **Haemoglobin level at birth is associated with short term outcomes and mortality in preterm infants.** *BMC Med.* 2015; **13**: 16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- National Neonatal Audit Programme Annual Report 2020 - on 2019 Data. 2020.
[Reference Source](#)
- Helenius K, Longford N, Lehtonen L, et al.: **Association of early postnatal transfer and birth outside a tertiary hospital with mortality and severe brain injury in extremely preterm infants: observational cohort study with propensity score matching.** *BMJ.* 2019; **367**: I5678.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Costeloe K, Hennessy E, Gibson AT, et al.: **The EPICure Study: Outcomes to Discharge From Hospital for Infants Born at the Threshold of Viability.** *Pediatrics.* 2000; **106**(4): 659–71.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Howarth C, Banerjee J, Aladangady N: **Red Blood Cell Transfusion in Preterm Infants: Current Evidence and Controversies.** *Neonatology.* 2018; **114**(1): 7–16.
[PubMed Abstract](#) | [Publisher Full Text](#)

40. Bakshi S, Koerner T, Knee A, *et al.*: **Effect of Fluid Bolus on Clinical Outcomes in Very Low Birth Weight Infants.** *J Pediatr Pharmacol Ther.* 2020; **25**(5): 437–444. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
41. Northern Neonatal Nursing Initiative (N. N. Initiative): **Systolic blood pressure in babies of less than 32 weeks gestation in the first year of life. Northern Neonatal Nursing Initiative.** *Arch Dis Child - Fetal Neonatal Ed.* 1999; **80**(1): F38–F42. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
42. Vesoulis ZA, El Ters NM, Wallendorf M, *et al.*: **Empirical estimation of the normative blood pressure in infants <28 weeks gestation using a massive data approach.** *J Perinatol.* 2016; **36**(4): 291–295. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
43. Jammeh ML, Adibe OO, Tracy ET, *et al.*: **Racial/ethnic differences in necrotizing enterocolitis incidence and outcomes in premature very low birth weight infants.** *J Perinatol.* 2018; **38**(10): 1386–1390. [PubMed Abstract](#) | [Publisher Full Text](#)
44. Goldstein GP, Pai VV, Liu J, *et al.*: **Racial/ethnic disparities and human milk use in necrotizing enterocolitis.** *Pediatr Res.* 2020; **88**(Suppl 1): 3–9. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
45. Cuna A, Sampath V, Khashu M: **Racial Disparities in Necrotizing Enterocolitis.** *Front Pediatr.* 2021; **9**: 633088. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
46. Parkerson S, Philip R, Talati A, *et al.*: **Management of Patent Ductus Arteriosus in Premature Infants in 2020.** *Front Pediatr.* 2021; **8**: 590578. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
47. Concato J, Horwitz RJ: **Beyond randomised versus observational studies.** *Lancet.* 2004; **363**(9422): 1660–1661. [PubMed Abstract](#) | [Publisher Full Text](#)
48. Garafova A, Kornanova E, Chovancova D, *et al.*: **Relationships between antenatal corticosteroids and catecholamine blood pressure support in neonates: considering of maternal stress-related diseases.** *Stress.* 2020; **23**(6): 694–699. [PubMed Abstract](#) | [Publisher Full Text](#)
49. Greenough A, Gamsu HR, Greenall F: **Investigation of the Effects of Paralysis by Pancuronium on Heart Rate Variability, Blood Pressure and Fluid Balance.** *Acta Paediatr Scand.* 1989; **78**(6): 829–834. [PubMed Abstract](#) | [Publisher Full Text](#)
50. Simons SHP, Roofthoof DW, van Dijk M, *et al.*: **Morphine in ventilated neonates: its effects on arterial blood pressure.** *Arch Dis Child Fetal Neonatal Ed.* 2006; **91**(1): F46–F51. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
51. Rabe H, Gyte GM, Díaz-Rossello JL, *et al.*: **Effect of timing of umbilical cord clamping and other strategies to influence placental transfusion at preterm birth on maternal and infant outcomes.** *Cochrane Database Syst Rev.* 2019; **9**(9): CD003248. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status:  

Version 2

Reviewer Report 25 May 2023

<https://doi.org/10.3310/nihropenres.14572.r29254>

© 2023 Dempsey E. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Eugene M. Dempsey 

¹ INFANT Research Centre, Department of Paediatrics and Child Health, University College Cork, Cork, County Cork, Ireland

² Department of Neonatology, Cork University Maternity Hospital, Cork, Ireland

My previous concerns were addressed. There is one typo in table no.4: Length of stay for SCBU

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Cardiovascular support in. preterm infants

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 22 May 2023

<https://doi.org/10.3310/nihropenres.14572.r29255>

© 2023 Mahoney L. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Liam Mahoney

University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK

The authors have amended the manuscript in line with previous comments.

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Interest in neonatal haemodynamics

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 13 April 2023

<https://doi.org/10.3310/nihropenres.14485.r29154>

© 2023 Mahoney L. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Liam Mahoney**

¹ University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK

² University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK

Thank you for asking me to review this manuscript. This is an interesting study that adds to the body of literature surrounding this important area of neonatology that is contentious and under-researched.

Many of the suggestions I had for the researchers whilst I was reviewing the article are actually acknowledged in the limitations/discussions sections of the article. This mainly relates to the differences they could not account for between the two centres such as feeding practices, PDA assessment/treatment and also the retrospective nature of the study.

One of the pieces of data I was hoping the researchers could expand on was pregnancy complications which is significantly different between the two groups. The researchers collected data on antenatal doppler findings, chorioamnionitis, hypertension, antepartum haemorrhage APH, but I may be mistaken but in table 1 these specific complications do not make up all of the pregnancy complications between the two groups. Could the researchers include more data on the specific pregnancy complications that were different between the two groups.

The primary outcome was death or parenchymal brain abnormality on cranial ultrasound scan. With the latter could the researchers define exactly what they mean by parenchymal brain abnormality. I am presuming all grades of IVH, PVL etc., but could they be explicit here.

With regards to the statistics the researchers use parametric tests. Could they confirm that the data was normally distributed and did they test for this.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Interest in neonatal haemodynamics

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 13 March 2023

<https://doi.org/10.3310/nihropenres.14485.r29010>

© 2023 Dempsey E. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Eugene M. Dempsey 

¹ INFANT Research Centre, Department of Paediatrics and Child Health, University College Cork, Cork, County Cork, Ireland

² Department of Neonatology, Cork University Maternity Hospital, Cork, Ireland

³ INFANT Research Centre, Department of Paediatrics and Child Health, University College Cork, Cork, County Cork, Ireland

⁴ Department of Neonatology, Cork University Maternity Hospital, Cork, Ireland

Thank you for asking me to review this manuscript. It compares two approaches to blood pressure management, one unit aiming to maintain mean BP greater than 30 mmhg and the other a more permissive approach to management. The manuscript is generally well presented. The strength lies in the numbers of included patients. The greatest limitation is the fact that it compares individual unit practices, and as such is open to many potential confounders. These need to be highlighted further in the limitations section of their discussion. The main findings are an increased incidence of NEC and a reduction in the incidence of PDA treatment in the permissive group. Many factors influence both of these outcomes and its important to acknowledge these in this type of study.

Some of the following confounders should be acknowledged.

- Delivery room ventilatory strategies
- Thermoregulation in Delivery room
- Umbilical Cord management
- Ventilation strategies in the neonatal unit
- Feeding strategies in particular breast milk use, age at commencement, donor use
- Probiotic use

Some commentary on the inotrope use overall should be highlighted. The overall percentage use was 40% in the permissive and 62% in the active. These are very high rates. No detail is provided on duration of time prior to commencing an agent. Did the individual units have a policy on duration of time BP below threshold?

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Partly

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

No source data required

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Cardiovascular support in. preterm infants

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.
